X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
A psychoactive compound, Lucid-PSYCH (formerly Lucid-201) has been selected by FSD to advance its research into the treatment of major depressive disorders based on analysis of the drug candidate’s pharmaceutical and metabolic properties.
Lead Product(s): Lucid-PSYCH
Therapeutic Area: Psychiatry/Psychology Product Name: Lucid-201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: FSD Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 19, 2021
Details:
Aptorum with Covar Pharmaceuticals and in alliance with the University of Hong Kong plans to perform more preclinical experiments on selected small drug molecules to combat COVID-19 infection.
Lead Product(s): SACT-COV19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aptorum
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
